经导管与外科主动脉瓣置换的成本与边际贡献比较
基于2012年Medicare索赔数据,倾向性匹配比较TAVR与SAVR患者的医院成本与支付。TAVR医院成本中位数50,200美元高于匹配SAVR的45,500美元(P<.01),但TAVR支付中位数49,500美元低于SAVR的50,400美元(P<.01)。TAVR边际贡献中位数为-3,380美元,SAVR为2,390美元(P<.01)。
要点
- TAVR医院成本中位数50,200美元,高于匹配SAVR的45,500美元(P<.01)。
- TAVR支付中位数49,500美元,低于SAVR的50,400美元(P<.01)。
- TAVR边际贡献中位数-3,380美元,SAVR为2,390美元(P<.01)。
核心结论
- 在风险水平相似的SAVR Medicare患者中,TAVR与更高的医院成本相关,尽管ICU和住院时间更短。
研究设计与样本
- 基于2012年1月至12月Medicare索赔数据,采用倾向性评分匹配比较TAVR与SAVR患者的医院成本、支付与结局。
主要发现
- 2012年Medicare为4083例TAVR患者支出215,770,200美元。
- TAVR医院成本中位数50,200美元(IQR 39,800-64,300),高于匹配SAVR的45,500美元(IQR 34,500-63,300),P<.01。
- TAVR术后住院时间中位数5天(IQR 4-8),短于SAVR的7天(IQR 5-9),P<.01。
- TAVR总ICU时间中位数2天(IQR 0-5),短于SAVR的3天(IQR 1-6),P<.01。
- TAVR支付中位数49,500美元(IQR 36,900-64,600),低于SAVR的50,400美元(IQR 37,400-65,800),P<.01;边际贡献中位数分别为-3,380美元与2,390美元(P<.01)。
临床怎么用
- TAVR可使住院和ICU时间缩短,但医院成本更高且支付更低,需关注其对医院财务的净影响。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To compare the cost of and payments for transcatheter aortic valve replacement (TAVR), a novel and expensive technology, and surgical aortic valve replacement (SAVR). METHODS: Medicare claims provided hospital charges, payments, and outcomes between January and December 2012. Hospital costs and charges were estimated using hospital-specific cost-to-charge ratios. Costs and payments were examined in propensity score- matched TAVR and SAVR patients. RESULTS: Medicare spent $215,770,200 nationally on 4083 patients who underwent TAVR in 2012. Hospital costs were higher for TAVR patients (median, $50,200; interquartile range [IQR], $39,800-$64,300) than for propensity-matched SAVR patients ($45,500; IQR, $34,500-$63,300; P < .01), owing largely to higher estimated medical supply costs, including the implanted valve prosthesis. Postprocedure hospital length of stay (LOS) length was shorter for TAVR patients (median, 5 days [IQR, 4-8 days] vs 7 days [IQR, 5-9 days]; P < .01), as was total intensive care unit (ICU) LOS (median, 2 days [IQR, 0-5 days] vs 3 days [IQR, 1-6 days]; P < .01). Medicare payments were lower for TAVR hospitalizations (median, $49,500; IQR, $36,900-$64,600) than for SAVR (median, $50,400; IQR, $37,400-$65,800; P < .01). The median of the differences between payments and costs (contribution margin) was -$3380 for TAVR hospitalizations and $2390 for SAVR hospitalizations (P < .01). CONCLUSIONS: TAVR accounted for $215 million in Medicare payments in its first year of clinical use. Among SAVR Medicare patients at a similar risk level, TAVR was associated with higher hospital costs despite shorter ICU LOS and hospital LOS. Overall and/or medical device cost reductions are needed for TAVR to have a net neutral financial impact on hospitals.
引用
- McCarthy FH, Savino DC, Brown CR, et al. Cost and contribution margin of transcatheter versus surgical aortic valve replacement. J Thorac Cardiovasc Surg. 2017. PMID: 28712581. doi:10.1016/j.jtcvs.2017.06.020
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。